Immunological and clinical characteristics of severe thrombocytopenia in neonates with Kasabach–Merritt phenomenon
-
By
-
Cancan Li
-
Yang Li
-
Yan Huang
-
Yuanyuan Gao
-
Lili Li
-
Jinhui Hu
-
Ting Feng
-
Zhenhong Zhu
-
Haifeng Geng
-
June 29, 2026
-
Clinical Scorecard: Immunological Profiles and Clinical Features of Severe Thrombocytopenia in Neonates Diagnosed with Kasabach–Merritt Phenomenon
At a Glance
| Category | Detail |
|---|
| Condition | Kasabach-Merritt Phenomenon |
| Key Mechanisms | Severe thrombocytopenia associated with vascular tumors and immune dysregulation. |
| Target Population | Neonates diagnosed with Kasabach-Merritt phenomenon. |
| Care Setting | Multicenter retrospective study in pediatric hospitals. |
Key Highlights
- KMP neonates showed reduced CD3+CD4+ and CD3−CD19+ proportions and lower IgG levels.
- Severe KMP group had larger lesion diameters and higher lymphocyte percentage, PCT, CKMB, and ferritin.
- Prolonged APTT and elevated ferritin were independently associated with severe thrombocytopenia.
- Complete remission was achieved in 78.1% of KMP neonates.
Guideline-Based Recommendations
Diagnosis
- Diagnosis based on significant thrombocytopenia and consumptive coagulopathy associated with vascular tumors.
Management
- Treatment outcomes compared between severe and non-severe KMP groups.
Monitoring & Follow-up
- Monitor platelet counts and associated laboratory findings for disease activity.
Risks
- Increased risk of spontaneous and persistent bleeding due to severe thrombocytopenia.
Patient & Prescribing Data
Neonates diagnosed with KMP.
Clinical features and immunological profiles linked to treatment outcomes.
Clinical Best Practices
- Early recognition of severe thrombocytopenia for better risk stratification.
- Individualized treatment planning based on immunological profiles.
Related Resources & Content
